A world of possibilities
Navigating life sciences and medtech to the extraordinary—driven by creativity, curiosity, and the courage to build a fulfilling journey.
-
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Published in Nature Medicine (June 3, 2025) — this paper reports a first-of-its-kind clinical proof of concept for an AI-discovered therapeutic, marking a major milestone in AI-driven drug discovery and translational medicine. What the study…
-
Soluble TCRs and Methods of Use Thereof
What It Covers This patent application describes soluble T-cell receptors (TCRs) and related compositions and methods — a technology central to novel immunotherapy approaches that can be used therapeutically or diagnostically in cancer and infectious…
-
Anti‑TLR9 Agents and Compositions and Methods for Making and Using the Same
Assignee: BioLegend, Inc. (San Diego, California, USA)Patent Number: 12,441,806 B2Filed: March 22, 2021Issued: October 14, 2025 Inventors: Nicole Vivienne Acuff, Anagha Ashok Divekar, Takatoku Oida What the Patent Covers This patent protects compositions and methods involving anti‑TLR9 agents — particularly monoclonal…
BioTech IP Review 